Teligent Pharma Recalls Betamethasone Dipropionate Ointment Due to Impurity Failure
Teligent Pharma is recalling Betamethasone Dipropionate Ointment 0.05% because it failed impurity specifications for a known degradation product.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Teligent Pharma, Inc. is recalling Betamethasone Dipropionate Ointment USP, 0.05% (Augmented), packaged in 15-gram tubes. The recall involves 104,784 tubes distributed nationwide in the United States. The specific lots affected are 14297 (expiring 9/2021), 15372 (expiring 3/2022), and 15841 (expiring 8/2022).
The recall was initiated because the product failed impurity and degradation specifications. Specifically, the product tested out of specification (OOS) for the known impurity Betamethasone 17-propionate. The U.S. Food and Drug Administration has classified this as a Class III recall, which indicates that use of or exposure to the product is not likely to cause adverse health consequences.
Consumers and healthcare providers should stop using the recalled product and return it to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- Betamethasone Dipropionate Ointment USP, 0.05% (Augmented), packaged in 15 grams tubes, Manufactured by: Teligent Pharma, Inc. Buena, New Jersey 08310, NDC 52565-019-15
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Steroid
- Hazard
- Affected units
- 104,784
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: 14297
- Exp 9/2021
- 15372
- Exp 3/2022
- 15841
- Exp 8/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Teligent Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Teligent Pharma, Inc.
See all →- ModerateDesonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateTriamcinolone Acetonide Cream USP 0.1% Recall — Stability Study Discontinuation
FDA (Drugs) · 2022-03-30
- ModerateTriamcinolone Acetonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateDesoximetasone Ointment USP Recalled by Teligent Pharma
FDA (Drugs) · 2022-03-30
- HighDiflorasone Diacetate Ointment recalled due to discontinued stability studies
FDA (Drugs) · 2022-03-30
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17